Archive \ Volume.12 2021 Issue 2

An Overview on Pelvic Inflammatory Disease Diagnosis and Management Approach

, , , , , , , ,


In females, pelvic inflammatory disease (PID) is defined as inflammation and/or infection that affects the upper genital area, including the ovaries, uterus, and fallopian tubes. pelvic inflammatory disease can be caused by a variety of microorganisms found in sexually transmitted diseases, the most prevalent of which is Chlamydia trachomatis. We aim to review literature searching for the etiology of pelvic inflammatory disease, risk factors, diagnosis, clinical presentation, and management regarding this disease. PubMed database was used for the selection procedure of appropriate articles, and the following keywords were used in the mesh ((“Pelvic inflammatory disease” [Mesh]) (“Evaluation"[Mesh] AND/OR "Etiology"[Mesh] AND/OR "Risk factors"[Mesh] AND/OR "Diagnosis"[Mesh] AND/OR "Management"[Mesh])). Even though the pelvic inflammatory disease is relatively easy to treat, the core of the problem resides in late or misdiagnosis of the issue. Following the most recent guidelines in evaluating the patients for PID help the medical staff to provide the best management plan the patient needs and to prevent the unfortunate possible sequelae.

How to cite:
Alshammari SM, Alrajhi NN, Al-Rumayh SS, Alosaimi MA, Alsharyufi RM, Bukhari YS, et al. An Overview on Pelvic Inflammatory Disease Diagnosis and Management Approach. Arch Pharm Pract. 2021;12(2):103-5.
Alshammari, S. M., Alrajhi, N. N., Al-Rumayh, S. S., Alosaimi, M. A., Alsharyufi, R. M., Bukhari, Y. S., Aldhrye, S. A., Kasem, G. H., & Aljohani, R. M. J. (2021). An Overview on Pelvic Inflammatory Disease Diagnosis and Management Approach. Archives of Pharmacy Practice, 12(2), 103-105.

Download Citation

1.        Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002;186(5):929-37. doi:10.1067/mob.2002.121625

2.        Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201(Suppl 2):S134-55. doi:10.1086/652395

3.        Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol. 2013;178(3):484-92. doi:10.1093/aje/kws583

4.        Soper DE. Pelvic inflammatory disease. Obstet Gynecol. 2010;116(2 Pt 1):419-28. doi:10.1097/AOG.0b013e3181e92c54

5.        Kamel RM. Screening for Chlamydia trachomatis infection among infertile women in Saudi Arabia. Int J Womens Health. 2013;5:277-84. doi:10.2147/IJWH.S46678

6.        Alfarraj DA, Somily AM, Alssum RM, Abotalib ZM, El-Sayed AA, Al-Mandeel HH. The prevalence of Chlamydia trachomatis infection among Saudi women attending the infertility clinic in Central Saudi Arabia. Saudi Med J. 2015;36(1):61-6. doi:10.15537/smj.2015.1.9967

7.        Lestari SW, Japari A, Makes D, Wasian G, Hartono J, Supardi P, et al. Imaging of the male genital tract: a review of the mechanism of sperm quality impairment in infertility. Int J Pharm Phytopharmacol Res. 2020;10(1):87-96.

8.        Taylor-Robinson D, Jensen JS, Svenstrup H, Stacey CM. Difficulties experienced in defining the microbial cause of pelvic inflammatory disease. Int J STD AIDS. 2012;23(1):18-24. doi:10.1258/ijsa.2011.011066

9.        Taylor BD, Ness RB, Darville T, Haggerty CL. Microbial correlates of delayed care for pelvic inflammatory disease. Sex Transm Dis. 2011;38(5):434-8. doi:10.1097/OLQ.0b013e3181ffa7c7

10.      Ness RB, Hillier SL, Kip KE, Soper DE, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104(4):761-9. doi:10.1097/01.AOG.0000139512.37582.17

11.      Heinonen PK, Miettinen A. Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol. 1994;57(2):85-9. doi:10.1016/0028-2243(94)90048-5

12.      Katz DF. Human cervical mucus: research update. Am J Obstet Gynecol. 1991;165(6 Pt 2):1984-6. doi:10.1016/s0002-9378(11)90559-6

13.      Kuijsters NPM, Methorst WG, Kortenhorst MSQ, Rabotti C, Mischi M, Schoot BC. Uterine peristalsis and fertility: current knowledge and future perspectives: a review and meta-analysis. Reprod Biomed Online. 2017;35(1):50-71. doi:10.1016/j.rbmo.2017.03.019

14.      Das BB, Ronda J, Trent M. Pelvic inflammatory disease: improving awareness, prevention, and treatment. Infect Drug Resist. 2016;9:191-7. doi:10.2147/IDR.S91260

15.      Simms I, Stephenson JM, Mallinson H, Peeling RW, Thomas K, Gokhale R, et al. Risk factors associated with pelvic inflammatory disease. Sex Transm Infect. 2006;82(6):452-7. doi:10.1136/sti.2005.019539

16.      Mitchell C, Prabhu M. Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis, and treatment. Infect Dis Clin North Am. 2013;27(4):793-809. doi:10.1016/j.idc.2013.08.004

17.      Saraswat N, Sachan N, Chandra P. A Detailed Review on the rarely found Himalayan herb Selinum vaginatum: Its Active constituents, pharmacological uses, traditional and potential benefits. Pharmacophore. 2020;11(2):40-52.

18.      (CDC) C for DC and P. No TitlePelvic Inflammatory Disease (PID). Published 2021. Accessed August 16, 2021. Available from:

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.